Mohammed A Aleskandarany

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/257438/publications.pdf

Version: 2024-02-01

96 papers	3,485 citations	117453 34 h-index	155451 55 g-index
98 all docs	98 docs citations	98 times ranked	5707 citing authors

#	Article	IF	Citations
1	Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes. Clinical Cancer Research, 2009, 15, 2302-2310.	3.2	422
2	Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Research and Treatment, 2010, 119, 283-293.	1.1	193
3	CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Research and Treatment, 2008, 109, 325-335.	1.1	135
4	Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. Breast Cancer Research, 2012, 14, R3.	2.2	105
5	MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Research and Treatment, 2011, 127, 591-599.	1.1	93
6	MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. British Journal of Cancer, 2016, 114, 917-928.	2.9	91
7	A CD44âˆ’/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer. Breast Cancer Research and Treatment, 2012, 133, 979-995.	1.1	89
8	The prognostic significance of inflammation and medullary histological type in invasive carcinoma of the breast. European Journal of Cancer, 2009, 45, 1780-1787.	1.3	84
9	Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. Breast Cancer Research and Treatment, 2016, 159, 215-227.	1.1	81
10	Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKTâ€“YB1â€“MDR1 Signaling Pathway. Cancer Research, 2016, 76, 3057-3066.	0.4	75
11	MYC regulation of glutamineâ€“proline regulatory axis is key in luminal B breast cancer. British Journal of Cancer, 2018, 118, 258-265.	2.9	74
12	PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Research and Treatment, 2010, 122, 45-53.	1.1	73
13	FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. Breast Cancer Research and Treatment, 2011, 129, 11-21.	1.1	69
14	Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine. Pathobiology, 2018, 85, 23-34.	1.9	65
15	Heterogeneity of tumourâ€infiltrating lymphocytes in breast cancer and its prognostic significance. Histopathology, 2018, 73, 887-896.	1.6	62
16	Molecular Mechanisms Underlying Lymphovascular Invasion in Invasive Breast Cancer. Pathobiology, 2015, 82, 113-123.	1.9	59
17	Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. Histopathology, 2017, 71, 258-268.	1.6	58
18	Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. Cancer Immunology Research, 2017, 5, 292-299.	1.6	56

#	Article	IF	Citations
19	Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. Breast Cancer Research and Treatment, 2014, 145, 339-348.	1.1	55
20	Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study. Cancers, 2019, 11, 995.	1.7	53
21	Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Research and Treatment, 2011, 127, 407-416.	1.1	52
22	Cten signals through integrin-linked kinase (ILK) and may promote metastasis in colorectal cancer. Oncogene, 2011, 30, 2997-3002.	2.6	51
23	An approach to the diagnosis of spindle cell lesions of the breast. Histopathology, 2016, 68, 33-44.	1.6	50
24	Breast cancer intratumour heterogeneity: current status and clinical implications. Histopathology, 2018, 73, 717-731.	1.6	50
25	The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. Breast Cancer Research and Treatment, 2010, 121, 41-51.	1.1	47
26	Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. Breast Cancer Research and Treatment, 2017, 164, 341-348.	1.1	44
27	CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis. Breast Cancer Research and Treatment, 2011, 126, 47-54.	1.1	43
28	<scp>RECQL4</scp> helicase has oncogenic potential in sporadic breast cancers. Journal of Pathology, 2016, 238, 495-501.	2.1	43
29	Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. Molecular Cancer Therapeutics, 2015, 14, 1057-1065.	1.9	42
30	The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts. Modern Pathology, 2019, 32, 967-976.	2.9	41
31	DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. Breast Cancer Research and Treatment, 2015, 150, 81-90.	1.1	40
32	Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer. Oncotarget, 2016, 7, 13269-13284.	0.8	38
33	Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. Breast Cancer Research and Treatment, 2016, 159, 41-53.	1.1	37
34	Growth fraction as a predictor of response to chemotherapy in nodeâ€negative breast cancer. International Journal of Cancer, 2010, 126, 1761-1769.	2.3	36
35	Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. Scientific Reports, 2020, 10, 3009.	1.6	34
36	Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radioâ€resistance in breast cancer. Molecular Oncology, 2016, 10, 213-223.	2.1	33

#	Article	IF	Citations
37	The nucleolar-related protein Dyskerin pseudouridine synthase 1 (DKC1) predicts poor prognosis in breast cancer. British Journal of Cancer, 2020, 123, 1543-1552.	2.9	33
38	Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Research and Treatment, 2019, 174, 79-91.	1.1	32
39	Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. Carcinogenesis, 2016, 37, 63-71.	1.3	31
40	Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 493-502.	1.4	30
41	Prognostic stratification of oestrogen receptorâ€positive <scp>HER</scp>2â€negative lymph nodeâ€negative class of breast cancer. Histopathology, 2017, 70, 622-631.	1.6	30
42	The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. Breast Cancer Research and Treatment, 2016, 156, 9-20.	1.1	29
43	The role of PIP5K1Î±/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1Î± inhibitor. Oncogene, 2019, 38, 375-389.	2.6	29
44	TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. Breast Cancer Research and Treatment, 2012, 136, 419-427.	1.1	28
45	Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype. Pathobiology, 2020, 87, 218-231.	1.9	28
46	A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. British Journal of Cancer, 2019, 120, 1129-1136.	2.9	25
47	The prognostic significance of ALDH1A1 expression in early invasive breast cancer. Histopathology, 2020, 77, 437-448.	1.6	25
48	Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. Breast Cancer Research and Treatment, 2016, 157, 65-75.	1.1	24
49	Impact of breast cancer grade discordance on prediction of outcome. Histopathology, 2018, 73, 904-915.	1.6	24
50	Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ. Modern Pathology, 2019, 32, 1460-1472.	2.9	23
51	Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme. Histopathology, 2017, 70, 632-642.	1.6	22
52	A novel prognostic two-gene signature for triple negative breast cancer. Modern Pathology, 2020, 33, 2208-2220.	2.9	22
53	Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. Breast Cancer Research and Treatment, 2015, 151, 325-333.	1.1	21
54	Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells. Scientific Reports, 2017, 7, 43984.	1.6	20

#	Article	IF	Citations
55	Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer. Breast Cancer Research and Treatment, 2016, 158, 287-295.	1.1	19
56	Construction of tissue microarrays from core needle biopsies â€“ a systematic literature review. Histopathology, 2016, 68, 323-332.	1.6	18
57	The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer. Breast Cancer Research and Treatment, 2020, 179, 79-90.	1.1	18
58	Prognostic significance of KN motif and ankyrin repeat domains 1 (KANK1) in invasive breast cancer. Breast Cancer Research and Treatment, 2020, 179, 349-357.	1.1	18
59	Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers. Molecular Cancer Therapeutics, 2017, 16, 239-250.	1.9	17
60	Clinical utility of reverse phase protein array for molecular classification of breast cancer. Breast Cancer Research and Treatment, 2016, 155, 25-35.	1.1	16
61	Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer. British Journal of Cancer, 2017, 117, 1176-1184.	2.9	16
62	Pleomorphic adenomaâ€like tumour of the breast. Histopathology, 2016, 68, 405-410.	1.6	15
63	Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers. British Journal of Cancer, 2017, 117, 826-834.	2.9	14
64	Prognostic significance of nucleolar assessment in invasive breast cancer. Histopathology, 2020, 76, 671-684.	1.6	14
65	Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion. Modern Pathology, 2018, 31, 1675-1682.	2.9	13
66	Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer. Breast Cancer Research and Treatment, 2020, 179, 557-564.	1.1	13
67	Further evidence to support bimodality of oestrogen receptor expression in breast cancer. Histopathology, 2017, 70, 456-465.	1.6	12
68	Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. Breast Cancer Research and Treatment, 2018, 170, 525-533.	1.1	12
69	Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1Î±-dependent Induction of Polo-Like Kinase 4. Molecular Cancer Research, 2022, 20, 596-606.	1.5	12
70	Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy. Critical Reviews in Oncology/Hematology, 2009, 72, 76-82.	2.0	10
71	ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC. Breast Cancer Research, 2016, 18, 113.	2.2	10
72	Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer. Breast Cancer Research and Treatment, 2018, 172, 61-68.	1.1	10

#	Article	IF	Citations
73	Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer. British Journal of Cancer, 2019, 121, 776-785.	2.9	10
74	Chemokine (Câ€€ motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma. Journal of Pathology: Clinical Research, 2017, 3, 105-114.	1.3	9
75	Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes. British Journal of Cancer, 2018, 118, 1142-1151.	2.9	9
76	Machine learning-based prediction of breast cancer growth rate in vivo. British Journal of Cancer, 2019, 121, 497-504.	2.9	9
77	The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes. Breast Cancer Research and Treatment, 2020, 182, 581-589.	1.1	9
78	The Prognostic and Predictive Significance of PARP-1 in Locally Advanced Breast Cancer of Egyptian Patients Receiving Neoadjuvant Chemotherapy. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 571-579.	0.6	8
79	Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer. Breast Cancer Research and Treatment, 2019, 176, 63-73.	1.1	7
80	Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer. Breast Cancer Research and Treatment, 2021, 189, 621-630.	1.1	6
81	Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair. BMC Cancer, 2018, 18, 1027.	1.1	3
82	SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. British Journal of Cancer, 2019, 120, 728-745.	2.9	3
83	Ran GTPase is an independent prognostic marker in malignant melanoma which promotes tumour cell migration and invasion. Journal of Clinical Pathology, 2020, , jclinpath-2020-206871.	1.0	2
84	Molecular-Based Diagnostic, Prognostic and Predictive Tests in Breast Cancer. Molecular Pathology Library, 2015, , 177-195.	0.1	1
85	Molecular Pathology of Breast Cancer Metastasis. Molecular Pathology Library, 2015, , 271-289.	0.1	1
86	Overexpression of Carbonic Anhydrase IX is a Dismal Prognostic Marker in Breast Carcinoma in Egyptian Patients. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 405-413.	0.6	1
87	Prognostic significance of heat shock protein 90AA1 (HSP90Î±) in invasive breast cancer. Journal of Clinical Pathology, 2022, 75, 263-269.	1.0	1
88	O-55 Translational landscape of Epithelial Mesenchymal Transition in molecular classes of invasive breast cancer. European Journal of Cancer, Supplement, 2010, 8, 21.	2.2	0
89	Molecular Classification of Breast Cancer. Molecular Pathology Library, 2015, , 137-155.	0.1	0
90	Multi-institutional study of triple negative breast cancer stratification by a metric that quantifies cell cycling kinetics.. Journal of Clinical Oncology, 2016, 34, 1091-1091.	0.8	0

#	Article	IF	Citations
91	Identifying likely metastatic sites for triple negative breast cancers using immunohistochemical biomarkers.. Journal of Clinical Oncology, 2016, 34, 1092-1092.	0.8	0
92	Abstract B09: Multivariable Models for Predicting Likely Metastatic Sites for Triple Negative Breast Cancers. , 2017, , .		0
93	Abstract B08: Identifying high-risk triple negative breast cancer patients using a novel cycling kinetics metric. , 2017, , .		0
94	HER3-EGFR score to predict clinical outcomes in triple-negative breast cancer.. Journal of Clinical Oncology, 2017, 35, 11612-11612.	0.8	0
95	Dynamic relationship between cycling kinetics of triple-negative breast cancer and tumor infiltrating immune cells.. Journal of Clinical Oncology, 2017, 35, 1100-1100.	0.8	0
96	Prediction of breast cancer growth rate In vivo and its clinical implications.. Journal of Clinical Oncology, 2018, 36, e12581-e12581.	0.8	0